- DVAX Stock Page
Dynavax Technologies Corp. (NASDAQ:DVAX)
Last Update: 19 minutes ago
| Change: | -0.02 (-1.12%) |
| Last Trade: | 1.76 |
| Prev Close: | 1.78 |
| Share Volume: | 85,425 |
| Market Cap: | 70.06M |
| EPS (Earnings per share): | -1.49 |
| P/E (Price/earning ratio): | N/A |
| P/B (Price/book ratio): | 3.67 |
| Stock Price History | |
|---|---|
| Beta: | 1.37 |
| 52 week change: | -56.60% |
| 52 week high: | 6.55 |
| 52 week low: | 1.32 |
| 50 day moving avarage: | 1.63 |
| 200 day moving avarage: | 3.20 |
| Dividends | |
| Ex dividend date: | N/A |
| Dividend yield: | N/A |
| Dividend rate: | N/A |
| Share Statistics | |
| Avarage 10 day volume: | 122,157 |
| Shares outstanding: | 39,805,740 |
| Short interest date: | Jun 25, 2008 |
| Short shares: | 931,278 |
| Short ratio: | 6.80 |
| Short % of float: | 2.40% |
| Today | 5d | 1m | 3m | 6m | 1y | 5y |
Latest Headlines for DVAX
Company Profile
Sector: Healthcare
Industry: Drugs
Engage in commercialize innovative products
A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.
DVAX Headlines
-
May 16 at 8:30 ET
Dynavax to Discuss TOLAMBA(TM) Chamber Data; Update 2008 Outlook in Webcast This Morning -
May 16 at 7:01 ET
Dynavax TOLAMBA(TM) Chamber Study Misses Primary Endpoint; Company Updates 2008 Financial Outlook -
Apr 29 at 4:22 ET
Dynavax Announces First Quarter 2008 Financial Results -
Apr 17 at 9:14 ET
Dynavax and Merck & Co., Inc. Update Status of Clinical Hold of Investigational Vaccine HEPLISAV(TM) -
Mar 18 at 11:05 ET
BellwetherReport.com Free Analyst Review for DVAX, MDRX, NCC and MF -
Mar 17 at 4:08 ET
Dynavax and Merck & Co., Inc. Report Clinical Hold of Investigational Vaccine HEPLISAV -
Mar 17 at 3:30 ET
Dynavax, Merck: FDA Puts Clinical Hold On HEPLISAV Vaccine